<DOC>
	<DOC>NCT01124851</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and tolerability of the drug ABT-652 given once daily to people with excessive daytime sleepiness. Subjects will be randomized to either ABT-652 or placebo in three sequential dosing groups for a 1-week treatment period.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness</brief_title>
	<detailed_description />
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<criteria>Inclusion Criteria Has current diagnosis of an excessive daytime sleepiness disorder, including narcolepsy, idiopathic hypersomnia, and obstructive sleep apnea Age 18 to 60 years Exclusion Criteria Has significant suicidal ideation Has a history of substance abuse Has a history of a certain significant medical conditions, including uncontrolled psychiatric diseases or disorders Use of certain medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Sleep disorder</keyword>
</DOC>